5 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

3 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

4 - IMAC Holdings, Inc. (0001729944) (Issuer)

Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is addressed by the Palmetto GBA MolDx "Proteomics Testing" article (A59636). This milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into Ignite Proteomics. PLA codes like 0249U are essential building blocks for new diagnostics, as

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), announces the publication of a significant study in the British Journal of Cancer titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". This research underscores the critical importance of measuring functional protein activation within the AKT–mTOR signaling pathway to accurately predict patient responses to targeted cancer therapies. Advancing Precision Oncology Through Direct Protein Activation Measu

Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC Holdings" or the "Company") has launched Ignite Proteomics LLC ("Ignite"), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond. Why Proteins Matter – Beyond Genomics Although genomics (gene-based) testing has become common, patients and providers find it has not fully delivered on the promise of personalized care. One reason is that genetics only reveal potential – the blueprint of the disease – while proteins show what

FRANKLIN, TN, Nov. 22, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ("IMAC" or the "Company") (NASDAQ:BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 22, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Commi

FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ("IMAC" or the "Company") (NASDAQ:BACK) today announced that it has received an exception from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"). This exception extends the deadline for the Company to file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q") until February 17, 2025. The delay in filing is primarily due to complexities in preparing our financial statements for the second quarter as a result of events occurring during the period ended June 30, 2024 and certain staffing cha

Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC Holdings" or the "Company"), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC ("Ignite Proteomics"). This launch follows IMAC Holdings' strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study "Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer", demonstra

FRANKLIN, TN, Aug. 23, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ("IMAC" or the "Company") (NASDAQ:BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on August 21, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Commission (

Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o